Tradestie Institutional Equity Comparison Engine

ICCC vs IRIX โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-16 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

ICCC Overall Edge

ICCC Captures Institutional Edge (2โ€“0 Pillars ยท 8โ€“1 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Immucell Corp (ICCC) driven by superior Growth & Margin, Momentum & Technical. Fundamentally, ICCC trades at N/M Forward P/E with 15.2% operating margin (+11.5% YoY revenue) versus IRIX at N/M Forward P/E and -5.4% operating margin (-7.4% YoY). In options structure, ICCC sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro) against IRIX sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro).

Valuation Winner Tie
ICCC N/M vs IRIX N/M Fwd P/E
Growth & Margin Winner ICCC
Op Margin 15.2% vs -5.4% ยท YoY +11.5% vs -7.4%
Momentum & Technical Winner ICCC
1Y +88.8% vs -22.5% ยท 52W Pos 91% vs 8%
Options & Structure Winner Tie
UNCLASSIFIED (N/A IV) vs UNCLASSIFIED (N/A IV)
ICCC NASDAQ
Immucell Corp
In Vitro & In Vivo Diagnostic Substances
$11.42
+6.23% 1D
Market Cap $97.7M
1M Return +6.23%
1Y Return +88.76%
Forward P/E N/M
Unified AI Score
43.8 / 100 HOLD
Tech 15.0 Fund 48.0 Flow 50.0 Mom 50.0
IRIX NASDAQ
Iridex Corp
Electromedical & Electrotherapeutic Apparatus
$0.69
-0.32% 1D
Market Cap $12.1M
1M Return -15.57%
1Y Return -22.49%
Forward P/E N/M
Unified AI Score
51.8 / 100 HOLD
Tech 52.0 Fund 65.0 Flow 50.0 Mom 50.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: ICCC +88.76% IRIX -22.49% Spread: +111.25 pp (ICCC Lead)

Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant Revenue ($B) & Operating Margin (%)
Period ICCC Revenue IRIX Revenue ICCC Op. Margin IRIX Op. Margin Margin Edge
FY2019 $10M $40M -7.0% -20.7% ICCC
FY2020 $20M N/A -9.0% N/A ICCC
FY2021 $20M $40M 1.3% -18.1% ICCC
FY2022 $20M $60M -12.4% -13.2% ICCC
FY2023 $20M $50M -32.9% -19.3% IRIX
FY2024 $30M $50M -6.2% -17.1% ICCC
FY2025 $30M N/A 6.0% N/A ICCC
FY2026 N/A $50M N/A -4.9% IRIX

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: ICCC (8) vs IRIX (1)
Institutional Metric ICCC IRIX Criterion Row Winner
Market Capitalization Scale $97.7M $12.1M Larger Scale ICCC
Trailing P/E Ratio Valuation 56.6x N/M Lower Multiple ICCC
Forward P/E Ratio Valuation N/M N/M Lower Multiple Tie
Revenue Growth (YoY) Growth +11.5% -7.4% Higher Growth ICCC
Operating Margin (TTM) Profitability 15.2% -5.4% Higher Margin ICCC
Net Profit Margin Profitability 2.6% -6.9% Higher Margin ICCC
Return on Equity (ROE) Capital Efficiency 2.6% -73.2% Higher ROE ICCC
52-Week Range Position Momentum 91% ($5โ€“$12) 8% ($1โ€“$2) Stronger Trend ICCC
Beta / 30D Volatility Risk Regime 0.24ฮฒ ยท 46% Vol 0.66ฮฒ ยท 58% Vol Lower Realized Risk ICCC
Unified Institutional Score Composite Signal 43.8 / 100 (HOLD) 51.8 / 100 (HOLD) Higher Composite IRIX

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full ICCC vs IRIX Buy Guide
ICCC UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile N/A
IV Regime Unclassified
Live ICCC Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
IRIX UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile N/A
IV Regime Unclassified
Live IRIX Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither ICCC nor IRIX registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.